Comparison of breast magnetic resonance imaging clinical tumor size with pathologic tumor size in patients status post-neoadjuvant chemotherapy

被引：9

作者：

Williams, Mindy ^{[1
]}

Eatrides, Jennifer ^{[1
]}

Kim, Jongphil ^{[2
]}

Talwar, Harpreet ^{[1
]}

Esposito, Nicole ^{[1
]}

Szabunio, Margaret ^{[1
]}

Ismail-Khan, Roohi ^{[1
]}

Kiluk, John ^{[1
]}

Lee, Marie ^{[1
]}

Laronga, Christine ^{[1
]}

Khakpour, Nazanin ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Comprehens Breast Program, Dept Womens Oncol, Tampa, FL 33612 USA

[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Biostat, Tampa, FL 33612 USA

来源：

AMERICAN JOURNAL OF SURGERY | 2013年 / 206卷 / 04期

关键词：

Breast cancer; Magnetic resonance imaging; Neoadjuvant chemotherapy; SURGICAL ADJUVANT BREAST; PREOPERATIVE CHEMOTHERAPY; PROGNOSTIC-SIGNIFICANCE; INDUCTION CHEMOTHERAPY; CONSERVING SURGERY; RESIDUAL TUMOR; MRI EVALUATION; RE-EXCISION; CANCER; WOMEN;

D O I：

10.1016/j.amjsurg.2013.02.006

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

BACKGROUND: Neoadjuvant chemotherapy (NACT) is used in breast cancer to evaluate the response to treatment. We examined the usefulness of breast magnetic resonance imaging (MRI) in the evaluation of tumor response after NACT. METHODS: Breast MRIs of 87 women with MRI after NACT were reviewed. The Spearman coefficient was used for estimating the correlation between MRI and pathologic tumor sizes (ypTs). RESULTS: The median age was 50 years (range 25 to 83 years). The median MRI size was 1.25 cm (range 0 to 10 cm). The median ypT was 1.20 cm (range 0 to 10.4 cm). The Spearman coefficient between MRI and ypT was .78 (95% confidence interval, .67 to .85; P < .0001). MRI was found to have a positive predictive value of 92% and a negative predictive value of 64% for residual in-breast disease. The sensitivity and specificity of MRI were 86% and 77%, respectively. CONCLUSIONS: MRI correlates well with the final pathology and can be a useful modality to predict residual disease after NACT and aid in surgical planning. (C) 2013 Elsevier Inc. All rights reserved.

引用

页码：567 / 573

页数：7

共 38 条

[21] A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer [J].

Makris, A ;

Powles, TJ ;

Ashley, SE ;

Chang, J ;

Hickish, T ;

Tidy, VA ;

Nash, AG ;

Ford, HT .

ANNALS OF ONCOLOGY, 1998, 9 (11) :1179-1184

[22] Magnetic resonance imaging in the breast cancer patient: Curb your enthusiasm [J].

Morrow, Monica .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :352-353

[23] Advances in breast conservation therapy [J].

Newman, LA ;

Kuerer, HM .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (08) :1685-1697

[24] A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival [J].

Ogston, KN ;

Miller, ID ;

Payne, S ;

Hutcheon, AW ;

Sarkar, TK ;

Smith, I ;

Schofield, A ;

Heys, SD .

BREAST, 2003, 12 (05) :320-327

[25] Locoregional control of clinically diagnosed multifocal or multicentric breast cancer after neoadjuvant chemotherapy and locoregional therapy [J].

Oh, Julia L. ;

Dryden, Mark J. ;

Woodward, Wendy A. ;

Yu, Tse-Kuan ;

Tereffe, Welela ;

Strom, Eric A. ;

Perkins, George H. ;

Middleton, Lavinia ;

Hunt, Kelly K. ;

Giordano, Sharon H. ;

Oswald, Mary Jane ;

Domain, Delora ;

Buchholz, Thomas A. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (31) :4971-4975

[26] MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival [J].

Partridge, SC ;

Gibbs, JE ;

Lu, Y ;

Esserman, LJ ;

Tripathy, D ;

Wolverton, DS ;

Rugo, HS ;

Hwang, GE ;

Ewing, CA ;

Hylton, NM .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2005, 184 (06) :1774-1781

[27] The safety of breast-conserving surgery in patients who achieve a complete Pathologic response after Neoadjuvant chemotherapy [J].

Peintinger, Florentia ;

Symmans, W. Fraser ;

Gonzalez-Angulo, Ana M. ;

Boughey, Judy C. ;

Buzdar, Aman U. ;

Yu, T. Kuan ;

Hunt, Kelly K. ;

Singletary, S. Eva ;

Babiera, Gildy V. ;

Lucci, Anthony ;

Meric-Bernstam, Funda ;

Kuerer, Henry M. .

CANCER, 2006, 107 (06) :1248-1254

[28] A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients [J].

Pierga, Jean-Yves ;

Delaloge, Suzette ;

Espie, Marc ;

Brain, Etienne ;

Sigal-Zafrani, Brigitte ;

Mathieu, Marie-Christine ;

Bertheau, Philippe ;

Guinebretiere, Jean Marc ;

Spielmann, Marc ;

Savignoni, Alexia ;

Marty, Michel .

BREAST CANCER RESEARCH AND TREATMENT, 2010, 122 (02) :429-437

[29] Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27 [J].

Rastogi, Priya ;

Anderson, Stewart J. ;

Bear, Harry D. ;

Geyer, Charles E. ;

Kahlenberg, Morton S. ;

Robidoux, Andre ;

Margolese, Richard G. ;

Hoehn, James L. ;

Vogel, Victor G. ;

Dakhil, Shaker R. ;

Tamkus, Deimante ;

King, Karen M. ;

Pajon, Eduardo R. ;

Wright, Mary Johanna ;

Robert, Jean ;

Paik, Soonmyung ;

Mamounas, Eleftherios P. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (05) :778-785

[30] Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy [J].

Rosen, EL ;

Blackwell, KL ;

Baker, JA ;

Soo, MS ;

Bentley, RC ;

Yu, DH ;

Samulski, TV ;

Dewhirst, MW .

AMERICAN JOURNAL OF ROENTGENOLOGY, 2003, 181 (05) :1275-1282

← 1 2 3 4 →